Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy

Gunderson, 2004, Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis, J Clin Oncol, 22, 1785, 10.1200/JCO.2004.08.173 Douglass, 1986, Survival after postoperative combination treatment of rectal cancer, N Engl J Med, 315, 1294, 10.1056/NEJM198611133152014 Quirke, 2009, Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial, Lancet, 373, 821, 10.1016/S0140-6736(09)60485-2 MacFarlane, 1993, Mesorectal excision for rectal cancer, Lancet, 341, 457, 10.1016/0140-6736(93)90207-W Kariv, 2008, Postoperative radiotherapy for stage IIIA rectal cancer: is it justified?, Dis Colon Rectum, 51, 1459, 10.1007/s10350-008-9346-9 Merchant, 1999, T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy, J Gastrointest Surg, 3, 642, 10.1016/S1091-255X(99)80087-0 Sauer, 2004, Preoperative versus postoperative chemoradiotherapy for rectal cancer, N Engl J Med, 351, 1731, 10.1056/NEJMoa040694 Roh, 2009, Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03, J Clin Oncol, 27, 5124, 10.1200/JCO.2009.22.0467 Andre, 2004, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 350, 2343, 10.1056/NEJMoa032709 Andre, 2009, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J Clin Oncol Off J Am Soc Clin Oncol, 27, 3109, 10.1200/JCO.2008.20.6771 Haller, 2011, Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer, J Clin Oncol Off J Am Soc Clin Oncol, 29, 1465, 10.1200/JCO.2010.33.6297 Kuebler, 2007, Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07, J Clin Oncol Off J Am Soc Clin Oncol, 25, 2198, 10.1200/JCO.2006.08.2974 Lund, 2013, Determinants of adjuvant oxaliplatin receipt among older stage II and III colorectal cancer patients, Cancer, 119, 2038, 10.1002/cncr.27991 Petersen, 2012, Postoperative adjuvant chemotherapy in rectal cancer operated for cure, Cochrane Database Syst Rev, 3, 10.1002/14651858.CD004078.pub2 Bosset, 2014, Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study, Lancet, 10.1016/S1470-2045(13)70599-0 Bosset, 2006, Chemotherapy with preoperative radiotherapy in rectal cancer, N Engl J Med, 355, 1114, 10.1056/NEJMoa060829 Breugom, 2015, Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data, Lancet Oncol, 16, 200, 10.1016/S1470-2045(14)71199-4 Hong, 2014, Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial, Lancet Oncol, 15, 1245, 10.1016/S1470-2045(14)70377-8 Schmoll, 2014, Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival results at interim analysis, J Clin Oncol Off J Am Soc Clin Oncol, 32 Rodel, 2014, Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: results of the German CAO/ARO/AIO-04 randomized phase III trial, J Clin Oncol Off J Am Soc Clin Oncol, 32 Sargent, 2005, Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials, J Clin Oncol Off J Am Soc Clin Oncol, 23, 8664, 10.1200/JCO.2005.01.6071 Rectal Cancer. Version 2.2015. NCCN Clinical Practice Guidelines in Oncology [Internet]. 2015, February. Available from: www.nccn.org. Glimelius, 2013, Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 24, vi81, 10.1093/annonc/mdt240 NICE clinical guideline 131. Colorectal cancer: the diagnosis and management of colorectal cancer2015, February Available from: guidance.nice.org.uk/cg131. Glimelius, 2010, Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, v82, 10.1093/annonc/mdq170 Schmoll, 2012, ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making, Ann Oncol, 23, 2479, 10.1093/annonc/mds236 Murthy, 2004, Participation in cancer clinical trials: race-, sex-, and age-based disparities, JAMA, 291, 2720, 10.1001/jama.291.22.2720 Parry, 2011, Cancer survivors: a booming population, Cancer Epidemiol Biomarkers Prev, 20, 1996, 10.1158/1055-9965.EPI-11-0729 Graham, 2005, Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case–control study, Lancet, 365, 475, 10.1016/S0140-6736(05)70270-1 Lund, 2013, Identifying specific chemotherapeutic agents in Medicare data: a validation study, Med Care, 51, e27, 10.1097/MLR.0b013e31823ab60f Warren, 2002, Utility of the SEER-Medicare data to identify chemotherapy use, Med Care, 40 Warren, 2002, Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population, Med Care, 40 Sanoff, 2012, Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis, Cancer, 10.1002/cncr.27422 Sanoff, 2012, Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer, J Natl Cancer Inst, 104, 211, 10.1093/jnci/djr524 Sanoff, 2012, Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75years, J Clin Oncol, 30, 2624, 10.1200/JCO.2011.41.1140 Bach, 2002, Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations., Med Care, 40 Mandelblatt, 2002, Variations in breast carcinoma treatment in older Medicare beneficiaries: is it black or white, Cancer, 95, 1401, 10.1002/cncr.10825 Klabunde, 2000, Development of a comorbidity index using physician claims data, J Clin Epidemiol, 53, 1258, 10.1016/S0895-4356(00)00256-0 Haynes, 2014, Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998–2007, Cancer, 120, 1162, 10.1002/cncr.28545 Faurot, 2015, Using claims data to predict dependency in activities of daily living as a proxy for frailty, Pharmacoepidemiol Drug Saf, 24, 59, 10.1002/pds.3719 Sturmer, 2011, Nonexperimental comparative effectiveness research using linked healthcare databases, Epidemiology, 22, 298, 10.1097/EDE.0b013e318212640c Sato, 2003, Marginal structural models as a tool for standardization, Epidemiology, 14, 680, 10.1097/01.EDE.0000081989.82616.7d Sturmer, 2006, Insights into different results from different causal contrasts in the presence of effect-measure modification, Pharmacoepidemiol Drug Saf, 15, 698, 10.1002/pds.1231 Austin, 2011, An introduction to propensity score methods for reducing the effects of confounding in observational studies, Multivar Behav Res, 46, 399, 10.1080/00273171.2011.568786 Fine, 1999, A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 Cole, 2015, Estimation of the standardized risk difference and ratio in a competing risks framework: application to injection drug use and progression to AIDS after initiation of antiretroviral therapy, Am J Epidemiol, 181, 238, 10.1093/aje/kwu122 Stang, 2010, Common problems related to the use of number needed to treat, J Clin Epidemiol, 63, 820, 10.1016/j.jclinepi.2009.08.006 McGrath, 2015, Controlling time-dependent confounding by health status and frailty: restriction versus statistical adjustment, Am J Epidemiol, 182, 17, 10.1093/aje/kwu485 Schneeweiss, 2007, Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results, Med Care, 45, S131, 10.1097/MLR.0b013e318070c08e Sargent, 2001, A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients, N Engl J Med, 345, 1091, 10.1056/NEJMoa010957 McCleary, 2013, Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database, J Clin Oncol, 31, 2600, 10.1200/JCO.2013.49.6638